Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. (ATNM) on July 22, 2020. The report addresses a corporate governance event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is an executive appointment:
- Effective Date: July 22, 2020.
- Action: The Board of Directors appointed Steve O'Loughlin as Chief Financial Officer.
- Background: Mr. O'Loughlin has served as the Company's Principal Financial Officer since May 2017.
- Continuity: He will continue to serve as the Company's Principal Financial and Accounting Officer.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of Steve O'Loughlin's promotion to Chief Financial Officer.
- Confirm that Mr. O'Loughlin retains his role as Principal Financial and Accounting Officer.
- Review the company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains none.